Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
31.03
+1.69 (5.76%)
May 26, 2026, 4:00 PM EDT - Market closed

Stoke Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
32.08184.4236.568.7812.41-
Revenue Growth (YoY)
-83.20%404.50%316.34%-29.22%--
Gross Profit
32.08184.4236.568.7812.41-
Selling, General & Admin
72.4167.0948.7941.3238.9231.9
Research & Development
144.92137.9289.1382.2377.8454.17
Total Operating Expenses
217.33205.01137.93123.55116.7686.07
Operating Income
-185.25-20.59-101.37-114.77-104.36-86.07
Interest Income
14.2613.7612.649.913.120.12
Other Non-Operating Income (Expense)
-0.06-0.05-0.250.170.170.14
Total Non-Operating Income (Expense)
14.213.7112.3910.073.290.26
Pretax Income
-171.05-6.89-88.98-104.7-101.07-85.81
Provision for Income Taxes
-1.28-----
Net Income
-169.77-6.89-88.98-104.7-101.07-85.81
Net Income to Common
-169.77-6.89-88.98-104.7-101.07-85.81
Shares Outstanding (Basic)
615954443937
Shares Outstanding (Diluted)
595954443937
Shares Change (YoY)
3.14%9.65%22.76%13.11%5.87%9.71%
EPS (Basic)
-2.84-0.12-1.65-2.38-2.60-2.34
EPS (Diluted)
-2.81-0.12-1.65-2.38-2.60-2.34
Shares Outstanding
62.2458.9254.0345.9239.4436.9
Free Cash Flow
-147.744.92-87.05-82.68-35.83-68.11
Free Cash Flow Per Share
-2.510.76-1.61-1.88-0.92-1.85
Gross Margin
100.00%100.00%100.00%100.00%100.00%-
Operating Margin
-577.46%-11.16%-277.31%-1307.21%-841.24%-
Profit Margin
-529.20%-3.73%-243.42%-1192.47%-814.73%-
FCF Margin
-460.40%24.35%-238.15%-941.72%-288.82%-
EBITDA
-183.52-18.82-99.2-112.3-102.81-85.09
EBITDA Margin
-572.06%-10.21%-271.36%-1279.09%-828.78%-
EBIT
-185.25-20.59-101.37-114.77-104.36-86.07
EBIT Margin
-577.46%-11.16%-277.31%-1307.21%-841.24%-
Effective Tax Rate
0.75%0.00%0.00%0.00%0.00%0.00%
Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q